Endocannabinoid signalling and the deteriorating brain

Nat Rev Neurosci. 2015 Jan;16(1):30-42. doi: 10.1038/nrn3876.


Ageing is characterized by the progressive impairment of physiological functions and increased risk of developing debilitating disorders, including chronic inflammation and neurodegenerative diseases. These disorders have common molecular mechanisms that can be targeted therapeutically. In the wake of the approval of the first cannabinoid-based drug for the symptomatic treatment of multiple sclerosis, we examine how endocannabinoid (eCB) signalling controls--and is affected by--normal ageing and neuroinflammatory and neurodegenerative disorders. We propose a conceptual framework linking eCB signalling to the control of the cellular and molecular hallmarks of these processes, and categorize the key components of endocannabinoid signalling that may serve as targets for novel therapeutics.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aging
  • Animals
  • Brain Diseases / drug therapy*
  • Brain Diseases / metabolism*
  • Brain Diseases / pathology
  • Endocannabinoids / metabolism*
  • Humans
  • Signal Transduction / physiology*


  • Endocannabinoids